Bionomics Investor Presentation Deck
BNC210 PTSD Trial Overall Conclusions
No overall effect on primary endpoint of CAPS-5 total severity score at 12 weeks
Australian patients had a greater improvement over placebo than US patients
✓CAPS-5 statistically significant at Week 4 in Australians (p<0.05)
Evidence of antidepressant effect in high dose treatment group in total population
✓CAPS-5 Criterion D overall (negative alterations in cognitions and mood) statistically significant at Week 1 (p<0.05)
✓CAPS-5 Criterion D, Question 2 (persistent and exaggerated negative beliefs or expectations) statistically significant at
Week 1 (p=0.001)
✓CAPS-5 Criterion D, Question 4 (persistent negative emotional state) statistically significant at Weeks 4 and 8 (p<0.05)
Trend for anxiolytic effect in high dose treatment group in the total population
✓ Trend towards improvement on CAPS-5 Criterion E (marked alterations in arousal and reactivity), Question 3
(hypervigilance)
✓Trend towards improvement on CAPS-5 Criterion E, Question 4 (exaggerated startle response)
BNC210 was well tolerated in patients with PTSD
✓No trend for increased adverse events with treatment
restore
✓No evidence of cognitive impairment
✓ No evidence of suicidal ideation or behavior worsening
Potential reasons why clinically significant effects and trends seen at early time points did not translate into significant
primary endpoint on CAPS-5 at 12 Weeks
Inadequate overall blood exposure of BNC210
Lower compliance with liquid suspension formulation which needed to be taken with food
Bionomics
33View entire presentation